Editor-We read with interest the article by Drs Mahmoud and Mason 1 regarding dexmedetomidine (DEX) and its use in the paediatric setting. Their review comprehensively covers the applications, effects, and cautions in the use of DEX and suggests areas for future research, including its potential neuroprotective effects. In particular, two elements of this review were of interest to us: firstly, their mention of the use of DEX during invasive airway procedures where there is a need to maintain airway tone and avoid respiratory depression; and secondly, the current difference in licensing for DEX in the USA and Europe.
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We recently used DEX alongside local anaesthetic infiltration in a 71-yr-old woman who was undergoing a palmaris longus tendon transfer to her upper lip. She had developed lip incompetence following previous surgical resection and radiotherapy for a mandibular squamous cell carcinoma. Although initially listed for general anaesthesia, on the morning of surgery the patient informed us of a significant phobia of nausea and vomiting, and was highly motivated to have the procedure performed under local anaesthesia.
We anticipated a number of challenges in providing safe and sufficient sedation for this procedure. The patient had a potentially difficult airway, as a result of her previous surgery and radiotherapy. Preoperative examination revealed a Mallampati score of 3, Calder grade B, and only 2.5 cm of mouth opening. We also anticipated a lengthy procedure (∼2.5 h), and the requirement for surgery at two separate anatomical sites. In view of previous experience in critical care, we decided that dexmedetomidine (Dexdor; Orion Corporation, Espoo, Finland) would be the most appropriate agent; offering anxiolysis, moderate sedation, and analgesia, with lower risk of airway or respiratory embarrassment.
We initiated sedation in the anaesthetic room 15 min before going into theatre, at a rate of 7 μg kg
. We then titrated the rate upwards to the desired state of the patient being rousable to voice, which in this instance was 14 μg kg
. During the procedure, a 15% reduction in heart rate and 10% reduction in baseline systolic blood pressure were noted, but these parameters remained stable throughout; as Mahmoud and Mason 1 highlighted in their review, the need for pharmacological resuscitation did not occur. The surgeons were able to interact with the patient during the procedure, and the ability to converse with the patient proved most useful to the surgical team. We have included their thoughts here for completeness.
The palmaris longus tendon inset to the left lower lip aimed to recruit the range of mimetic excursion of the ipsilateral zygomaticus muscle group and transmit this to the lower lip. The challenge of judging the degree of tension to exert during inset of the tendon to deliver the optimal lower lip position both in rest and during smile function was aided by the ability to have the patient execute mimetic facial movements on command during the procedure. The level of sedation achieved with this agent (DEX) allowed for administration of adequate local anaesthesia at donor and recipient surgical sites, for effective rousing and interaction with the patient performing facial movements on verbal command when required, and for the patient to return rapidly to a sleep state between commands.
After surgery, we gradually reduced the rate of infusion in recovery, terminating it 45 min after completion of surgery.
On review that evening, the patient informed us that she had felt very comfortable during the procedure. She had no specific recall apart from the injections of local anaesthesia and of a comment made by one of the surgeons relating to the length of her palmaris longus tendon. She was highly satisfied with her sedation and surgery, and was discharged home that evening.
At postoperative outpatient review 2 weeks after surgery, she reported good cognitive and physical function after the procedure. She demonstrated improved lip competence with no change in hand grip, including playing 18 holes of golf within 7 days of the procedure and without impairment of her handicap! As stated in the review article, the current European License for DEX extends only for patients requiring light to moderate sedation or for the management of agitation and delirium in intensive care. 2 Within anaesthesia, it is yet to be licensed in the UK, although it is licensed for use in operating theatres in the USA. Within critical care, the ProDex, MiDex, and Sedcom studies have shown a reduced duration of mechanical ventilation with DEX compared with midazolam, a reduced prevalence of delirium compared with midazolam, a reduced time to extubation compared with propfol and midazolam, and an improved ability to communicate pain compared with propofol. 3 4 In the context of anaesthesia, DEX has been shown to reduce minimal alveolar concentration requirements and volatile use, postoperative opioid requirements in postanaesthesia care units, and postoperative nausea and vomiting. 5 Its use is also associated with a reduction in postoperative delirium in patients undergoing cardiac surgery. 6 In the patient described, DEX enabled us to provide a safe and successful anaesthetic that honoured the patient's wishes. There were no adverse cardiovascular side-effects, and the patient's postoperative reported experience was highly satisfying. We acknowledge that DEX is not rapidly titratable, which is evidenced by our need for 15-30 min of titration before the start of surgery. We also allowed a period of time for gradual termination of the infusion in recovery. Despite these time constraints, we cannot think of any other drug that would have achieved the same result. With emerging evidence of efficacy and value for its use outside of intensive care, we would suggest that a review and extension of its current European license should be considered.
Written consent for the description of the aforementioned patient was obtained from the patient. Editor-Lai and colleagues 1 are to be congratulated on a superbly conducted trial to assess the benefits or otherwise of using a stroke volume (SV) optimization strategy superimposed on a liberal baseline fluid regimen to improve the outcome after major surgery. However, we wonder whether the large amounts of fluid needed for such a strategy could result in harm to patients and certainly not benefit, as was suggested by their previous trial 2 and editorial. 3 We were interested to look at the volume of fluids administered during surgery in this trial and make some observations regarding a monitoring strategy designed to maintain tissue perfusion while avoiding fluid overload during major surgery. Table 2 of Lai and colleagues 1 shows that both groups of patients received 1 litre or more of preoperative crystalloids on the day of surgery. Intraoperative management of the patients in both groups resulted in the administration of an additional 4.5 litres of fluid during an average surgical duration of ∼3.5 h. Assuming that all this fluid was balanced salt solution, this would contain the equivalent of ∼6 days of normal Na + requirement for an average patient. In this study, this considerable sodium load was given over a few hours, and in addition, the intervention group received an additional 1000 ml of colloid. Presumably, this considerable amount of fluid was given to try to maintain blood pressure (BP) by replacing so-called 'third space loss'. However, it is now well known that this loss does not occur during elective surgery, as has been pointed out in recent reviews. [4] [5] [6] [7] Indeed, recent work on the endothelial glycocalyx suggests that giving these quantities of fluid may damage the layer and exacerbate fluid loss, and create a third space which was not there in the first place. 8 Thus one must question why, in this randomized controlled trial, such amounts of fluid were nonetheless given in both groups. It is interesting that the multicentre Optimise study no longer recommended these quantities of fluid, suggesting only 1.5 ml kg −1 h −1 of 'maintenance fluid'. 9 It is also interesting to note that despite these large amounts of fluid being administered to the patients in both groups, a very high percentage required the additional use of the vasoconstrictor metaraminol, presumably again to try and maintain the BP. In our experience, this drug has a predominant effect on systemic vascular resistance, and although it can be effective to restore BP, this is often achieved at the cost of a reduction in SV and cardiac output (CO). Additional fluid was given during the first operative day, in all amounting to >7 litre in total in both groups. Given that this is all saline-containing fluid, this would now represent more than 11 days of Na + requirement in the average patient administered over a single day. This excess of >900 mmol of Na + would have to be excreted at some stage by the patient. Most of this fluid clearly ended up in the interstitial space, ultimately resulting in the accumulation of a significant tissue oedema, which could account for a number of the complications noted in both groups. Fluid overload is known to have a detrimental effect on anastomotic healing. In addition, hyperchloraemic acidosis has been shown to reduce gastric blood flow and decrease gastric intramucosal pH in elderly surgical patients. In fact, so much baseline fluid was given in both groups that the additional amount administered to the intervention group had no beneficial effect on SV, CO, oxygen delivery (D O2 ), or mean arterial pressure (see Table 4 of Lai and colleagues), 1 and one could speculate increases the likelihood of causing complications in the goal directed therapy (GDT) arm. The message that 'third space' loss does not usually occur in elective surgery does not seem to have resulted in a universal change of intraoperative fluid management. The current sensible recommendation is that fluids should be administered cautiously and the dose individualized and its effects on the circulation carefully monitored. As it has been frequently pointed out, just because someone is fluid responsive it does not mean they need additional fluids. Fluid responsiveness is likely to be more evident in patients with a good cardiovascular system, who will then end up with additional fluids because they can cope with them. However, if the fluid is in fact unnecessary, this could lead to increasing complications, as noted in their previous study. 2 What is most interesting, however, is indicated in Table 4 of Lai and colleagues.
1 From the data in Table 4 we calculate that both groups started with a D O2 in the awake state of ∼530 ml m −2 body surface area. However, compared with the value of CO obtained before incision in both groups, a ∼35% reduction is seen after induction, as a result of the combined effects of reduction in SV and an additional decrease in heart rate. It is
